Send your comments and tips to whitecoat@globe.com
  Awards Beth Israel Deaconess Medical Ctr. Boston Medical Center Boston University Brigham and Women's Hospital Broad Institute Cambridge Health Alliance Caritas St. Elizabeth's Medical Ctr. Children's Hospital Boston Dana-Farber Cancer Institute Grants Harvard University Joslin Diabetes Center Lahey Clinic Mass. General Hospital Mass. Health Law McLean Hospital MIT New England Baptist Hospital Personnel Moves Public Health Research Short White Coat Tufts-New England Medical Center Tufts University UMass Memorial Medical Center University of Massachusetts VA Medical Centers    A Healthy Blog Running A Hospital Nature Network Boston SciBos - Corie Lok's blog Kevin, M.D. Blog, MD Dr. Flea's blog Nurse at small Your Child's Health Blog Healthy Children blog WBUR's CommonHealth Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram &
Gazette.
Boston Globe Health and Science staff:
Scott Allen Alice Dembner Carey Goldberg Liz Kowalczyk Stephen Smith Colin Nickerson Beth Daley Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor. Short White Coat blogger Ishani Ganguli  |
« Beth Israel Deaconess COO leaving | Main | Chief neurosurgeon leaves void at Springfield hospital » Friday, February 2, 2007Predicting which drugs will make itTo develop more successful drugs, you have to look at both the winners and the losers. But that means drug companies need to share their gold mine of information on unsuccessful medicines, two researchers from Children's Hospital Boston's Informatics Program say. Based on information about failed drugs, Dr. Asher D. Schachter and Marco F. Ramoni say they can predict which drugs in early development will be safe and effective. They make that case in the February Nature Reviews Drug Discovery, saying their model could help save $283 million per approved drug. "Suppressing negative data harms everyone," Schachter said. "Companies could reduce drug development costs and pass on some of those savings to the consumer." Schachter and Ramoni just founded Phorecaster, a consulting business that has no customers or profits yet. Schachter, a pediatric nephrologist, said to create their forecasting model they looked at data about early-stage drugs described in publications from the Tufts Center for the Study of Drug Development and other public sources. Posted by Elizabeth Cooney at 02:31 PM
|
